Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

If Egalet Wins At FDA, Arymo ER Still Might Not In Opioid Market

Executive Summary

Potential sales impact of even broadest possible label for oral, intranasal and intravenous abuse remains a question mark given that abuse-deterrent products remain only a small percentage of market.

Advertisement

Related Content

Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace
Abuse-Deterrent Opioids Effectiveness, Value To Get ICER Review
FDA Panel Nod For Egalet Opioid's Deterrence Claims Made Easier By Tablet Hardness
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
When Is An Abuse-Deterrent Claim FDA Approved?
Opioids With Abuse-Deterrent Labeling
OxyContin wins 'abuse-deterrent' label, but FDA bans older generic forms

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel